top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)

AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.

Click here now for the full details of this stock that’s set to rocket in the AI revolution…

Erin Jones Biography and Net Worth

Insider of Gritstone bio

Erin E. Jones, M.S., is the chief operating officer. He had served as Gritstone’s executive vice president of global regulatory affairs and quality since May 2016. Prior to Gritstone, from July 2014 to April 2016, Mr. Jones served as vice president, global head of regulatory affairs, medical writing, pharmacology and toxicology at Puma Biotechnology, Inc., or Puma, a public biopharmaceutical company. Prior to Puma, Mr. Jones served as director, regulatory affairs at BioMarin Pharmaceutical Inc. from July 2012 to July 2014. Earlier in his career, Mr. Jones held various positions at Genentech, Inc., or Genentech, a biotechnology corporation and subsidiary of Roche, including head of regulatory intelligence and leader of the HER Franchise Regulatory Group. Mr. Jones received a B.S. in microbiology and chemistry from the University of Pittsburgh and an M.S. in computer systems from Pennsylvania State University.

How old is Erin E. Jones?: Mr. Jones is currently 52 years old. There are 4 older executives and no younger executives at Gritstone bio. The oldest executive at Gritstone bio is Dr. Andrew R. Allen BCh, BM, M.D., MA, MRCP, Ph.D., Co-Founder, President, CEO & Director, who is 58 years old. Learn More on Erin E. Jones' age.
How do I contact Erin E. Jones?: The corporate mailing address for Mr. Jones and other Gritstone bio executives is 5858 HORTON STREET SUITE 210, EMERYVILLE CA, 94608. Gritstone bio can also be reached via phone at (510) 871-6100 and via email at [email protected]. Learn More on Erin E. Jones' contact information.
Has Erin E. Jones been buying or selling shares of Gritstone bio?: Erin E. Jones has not been actively trading shares of Gritstone bio within the last three months. Most recently, Erin Jones sold 1,000 shares of the business's stock in a transaction on Wednesday, December 1st. The shares were sold at an average price of $13.01, for a transaction totalling $13,010.00. Learn More on Erin E. Jones' trading history.
Are insiders buying or selling shares of Gritstone bio?: In the last year, Gritstone bio insiders bought shares 1 times. They purchased a total of 12,000 shares worth more than $22,800.00. The most recent insider tranaction occured on May, 23rd when insider Vassiliki Economides bought 12,000 shares worth more than $22,800.00. Insiders at Gritstone bio own 4.6% of the company. Learn More about insider trades at Gritstone bio.
Information on this page was last updated on 5/23/2023.

Erin E. Jones Insider Trading History at Gritstone bio

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
12/1/2021	Sell	1,000	$13.01	$13,010.00
11/1/2021	Sell	1,000	$11.14	$11,140.00

Erin E. Jones Buying and Selling Activity at Gritstone bio

Gritstone bio Company Overview

Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing vaccine-based immunotherapy candidates against cancer and infectious diseases. Its primary product candidate is GRANITE, an individualized immunotherapy candidate, which is in Phase 2/3 clinical trials for the treatment of microsatellite stable colorectal cancers; and has completed Phase 1/2 clinical trials for treating solid tumors. The company is also developing SLATE, an off-the-shelf immunotherapy candidate, which is in Phase 2 clinical trials for the treatment of metastatic solid tumors. In addition, it develops CORAL, a COVID-19 vaccine program; and a therapeutic vaccine candidate that is in Phase 1 clinical trials designed to treat and cure human immunodeficiency virus (HIV) infection. Gritstone bio, Inc. has a strategic collaboration with bluebird bio, Inc.; collaboration agreement with Gilead Sciences, Inc.; and license agreement with Genevant Sciences GmbH. The company was formerly known as Gritstone Oncology, Inc. and changed its name to Gritstone bio, Inc. in May 2021. Gritstone bio, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.

Today's Range

Now: $0.81

$0.73

$0.82

50 Day Range

MA: $1.94

$0.74

$2.84

2 Week Range

Now: $0.81

$0.67

$3.33

Volume

1,870,771 shs

Average Volume

2,832,378 shs

Market Capitalization

$79.72 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.38